The transcription factor GATA2 was reported to associate with coronary artery disease (CAD) in the family-based Genecard sample (Connelly et al. in PLoS Genet 2:e139, 2006). We asked whether GATA2 associates with sporadic cases of CAD in the Ottawa Heart Genomics Study (OHGS) and Cleveland Clinic (CC) populations. We genotyped the lead single nucleotide polymorphism (SNP) from Genecard, rs2713604 which is located in intron 5-6 of GATA2 in 600 CAD cases and 625 controls, as well as a tag SNP rs1573949 (r 2 = 0.87 in Caucasians of European ancestry in Utah from HapMap) in 1,136 cases and 1,162 controls in the OHGS1 population. A further 1,838 CAD cases and 913 controls derived from an independent sample combining genotypes from CC and OHGS2 populations were genotyped for rs1573949. Neither of the genotyped SNPs associates with CAD in the OHGS1 or CC/OHGS2 populations. Our data suggest that GATA2 does not contribute to the development of angiographic CAD among sporadic cases.
Introduction
Coronary artery disease (CAD) is the leading killer in industrialized nations (Murray and Lopez 1997) . It represents a major economic burden to health care delivery systems; the estimated annual expenditure for the management of its consequences is in excess of $100 billion in the United States (Lloyd-Jones et al. 2009 ). Coronary artery disease demonstrates a strong familial component even after adjustment for traditional risk factors (Murabito et al. 2005; Rissanen 1979; Shea et al. 1984; ten Kate et al. 1982 ; Thomas and Cohen 1955) . More nuanced screening of the population will aid in early identiWcation of patients at risk for development of CAD and initiation of treatment paradigms that could prevent its late sequelae. This is contingent upon deWning variation in the genetic blueprint that confers risk for development of disease. Unlike, simple Mendelian traits where the genetic variant is not only suYcient but necessary for the development of the phenotype of interest, coronary artery disease is a complex trait characterized by genetic modiWers that interact with environmental cues to only modulate the risk of disease. Thus far, many of the variants that have been identiWed to confer risk for coronary artery disease have not been successfully replicated in subsequent populations. Examples include the initial descriptions of disease association and subsequent non-association with polymorphisms in lymphotoxin-alpha (Clarke et al. 2006; Ozaki et al. 2002) and TNFSF4 (tumor necrosis factor superfamily, member 4) (Koch et al. 2008; Wang et al. 2005) . While this may reXect a weak biological eVect, it may also be secondary to the signiWcant phenotypic heterogeneity employed between studies. These sequence variants must be distinguished from those that show consistent association across populations, such as polymorphisms in PCSK9 (proprotein convertase subtilsin/ kexin type 9) (Cohen et al. 2006; Kathiresan 2008) and sequence variation at chromosome 9p21.3 (Helgadottir et al. 2007; Samani et al. 2007; McPherson et al. 2007 ). 9p21.3 has been successfully replicated across CAD subphenotypes (Helgadottir et al. 2007; Samani et al. 2007; McPherson et al. 2007) . It is of considerable interest to attempt to replicate loci that have been associated with coronary artery disease in independent populations across phenotypes. This aids in validating the locus in question in addition to pin-pointing the biology that underlies the association. That is, those loci that associate with angiographic coronary artery disease and not myocardial infarction, likely aVect the mechanisms that govern deposition of atheroma, whereas those that are associated with myocardial infarction but not atheromatous coronary artery disease likely aVect plaque rupture and/or thrombosis. Recently, sequence variants in GATA2 were shown to associate with familial coronary artery disease (Connelly et al. 2006) . We asked whether the same variants associate with sporadic angiographically deWned CAD.
Methods
This study was approved by the Research Ethics Board of the University of Ottawa Heart Institute and written informed consent was obtained from all study participants. Informed consent was approved from the CC institutional review board for the CC cohort. Males below the age of 55 years and females below the age of 65 years with at least one epicardial stenosis >50% were eligible to be cases. Controls were those who did not carry a diagnosis of CAD by the age of 65 years for male and 70 years for females. Specimens from Cleveland Clinic were obtained from subjects who were prospectively enrolled in GeneBank, a large and well-characterized clinical repository with clinical and longitudinal data comprised from consenting subjects undergoing elective diagnostic cardiac catheterization. All GeneBank participants gave written informed consent and the Institutional Review Board of the Cleveland Clinic approved the study protocol. Genomic DNA was puriWed from peripheral blood in all study participants. For the lead GATA2 SNP rs2713604, 600 cases and 625 controls were genotyped using the following primers: forward, 5Ј-CCC AGC CAC AAT ATC CAG C-3Ј and reverse, 5Ј-CAT AGT CCC ATC ACC AGA TGG C-3Ј by the polymerase chain reaction on a Roche Lightcycler (Roche Applied Science, Laval, QC, Canada). The tagging SNP rs1573949 was genotyped by the AVymetrix 6.0 array in 1,136 cases and 1,162 controls. Samples analyzed by the 6.0 arrays yielded an average call rate by the Birdseed algorithm of 99.3%. Population stratiWcation was analyzed by the principal components method using Eigenstrat (Price et al. 2006) . Prior to association analysis, SNPs were excluded if deviated from Hardy-Weinberg equilibrium (p < 0.001) in the control samples, or yielded an individual SNP call rate of <95%, or had MAF < 0.05 in either cases or controls. Associations between SNPs and CAD were analyzed with additive tests using a threshold of p < 0.001. Analyses were adjusted for gender, BMI, and smoking. Table 1 lists baseline characteristics for individuals genotyped for the GATA2 SNP rs2713604 by Lightcycler ® and for the linked SNP rs1573949 using AVymetrix ® 6.0 arrays, Triglycerides (mmol/L) 2.5 § 1.7 1.5 § 1.2 2.4 § 1.8 1.4 § 0.9 2.4 § 1.9 1.4 § 1.0 LDL-C (mmol/L) 3.7 § 1.1 3.7 § 1.5 3.8 § 1.1 3.6 § 1.2 3.9 § 1.2 3.6 § 1.4 respectively, in the OHGS 1 population. (Table 2) . Similarly, in an independent sample, the CC/OHGS2, the tagging SNP rs1573949 again demonstrates a higher frequency in controls than in cases and is not associated with risk for CAD (Table 2) . To show that these samples accurately detect variants associated with CAD, we conWrmed rs1333049 at 9p21 to be highly associated with CAD in both the OHGS1 and CC/OHGS2 samples.
Results
HDL-C (mmol/L) 1.2 § 0.6 1.5 § 0.4 1.1 § 0.4 1.5 § 0.5 1.1 § 0
Discussion
Neither the lead SNP, rs2713604, nor the tagging SNP, rs1573949, (r 2 = 0.87) are associated with angiographic coronary artery disease in the OHGS or the OHGS2/CC cohorts. Moreover, the frequency of each of the SNPs is higher among controls than in cases (i.e. in our dataset, the relative frequencies between cases and controls would suggest a protective eVect of this variant, if any). In the report by Connelly et al. the association was seen in a familybased sample, Genecard, where it is conceivable that genetic factors play a relatively greater role in determination of phenotype than in cohorts comprised by sporadic cases. The authors validate rs2713604 in a sporadic casebased sample. Furthermore, they have attempted to replicate this Wnding in the Intermountain Heart Collaborative Study. While the association was reported as suggestive, it did not meet the p < 0.05 threshold among those with the primary case phenotype versus controls; its signiWcance is further undermined by the fact that Bonferroni correction would demand a p-value of <0.0045 given that 11 SNPs were genotyped simultaneously (Horne et al. 2009 ). While the association is nominally signiWcant in the Cathgen sample, it, too, does not achieve statistical signiWcance once corrected for multiple hypothesis testing by the Bonferroni method. The authors compared 656 Cathgen spontaneous cases to 410 controls and found a nominally signiWcant association (Connelly et al. 2006) . We have compared 3,574 cases and 2,700 controls and therefore our inability to detect association is not due to insuYcient statistical power. Moreover, it is noteworthy that in each of our subpopulations, the frequency of the polymorphisms in GATA2 is higher among controls than cases, suggesting a protective rather than a risk-conferring action. The adequacy of our populations to detect polymorphisms associated with CAD is conWrmed by the robust association seen with sequence variation at 9p21 with angiographic CAD in both OHGS1 and CC/OHGS2 (Table 3) .
Few loci have been replicated across populations. The great majority have yielded association that is far less consistent. This may be due to phenotypic heterogeneity between studies; while some studies interrogated CAD populations deWned by angiography, others used myocardial infarction-based populations. In this instance, the case deWnitions are fairly similar in that in both the OHGS and the Cathgen /Genecard samples the cases are those with signiWcant atheromatous burden detected by coronary angiography. However, in the Cathgen sample the age of 55 years is used as a threshold for both males and females, while in the OHGS, a threshold of 65 years is used for females. It is highly unlikely that the lack of even nominal association could be explained on this basis in the OHGS. It should be noted that the Cathgen and Genecard samples are ethnically heterogeneous, including a signiWcant number of American Indians, African Americans and Asians; the OHGS and CC populations are exclusively Caucasian-derived. Moreover, at inception diabetics were excluded from the OHGS and CC populations in order to identify genetic variants that predisposed uniquely to CAD; the Cathgen and Genecard populations include a signiWcant number of diabetics. Though unlikely, it is possible that the observation noted by the Genecard/Cathgen investigators represents a race-speciWc or diabetes dependent association.
A weak biological eVect of the variant of interest can also result in the inability to consistently replicate association; if each cycle of replication was undertaken in large sample sets, then statistically signiWcant associations could be replicated. Alternatively, meta-analyses can be performed that incorporate data from multiple sources. This assumes, of course, that the variant does elicit an eVect, albeit mild, and that the seminal association is not spurious. Once genetic association is established, the mechanisms that underlie the association must be established as this will improve our understanding of the pathogenesis of CAD and will possibly lead to the identiWcation of novel therapeutic targets. Secondly, the use of genetic markers in the clinical arena may be useful in clinical risk assessment. This would require demonstrating the incremental beneWt of testing for the variant of interest allied with standard tools of risk estimation such as the Framingham risk score in prospective cohorts. Before such studies are undertaken consistent association in a case-control format is necessary.
In genetic association studies, it is possible that the variant of interest is merely a surrogate for the bona Wde biological agent and its eventual identiWcation may facilitate subsequent replication as the statistical association may well be more robust. This may be the case with GATA2 although it remains a good candidate, given its expression in the aortic endothelial and smooth muscle cells.
In order to develop a comprehensive inventory of the genetic variants that aVect CAD-related phenotypes, alliances will need to be formed in order to develop large datasets limited to speciWc CAD-related phenotypes. This will facilitate the reliable identiWcation disease-causing variants, including those that elicit a mild biologic action. 
